Copixa 5 mg Tablet is an anticoagulant that reduces the blood's tendency to form harmful clots. It is used in conditions where clot prevention is important for health.
There are 16 brands of Apixaban listed in Bangladesh. 7 of them have a lower unit price than Copixa 5 mg Tablet. The lowest listed price is Antixa 2.5 mg Tablet at ৳ 10.00 per unit.
What is Copixa 5 mg Tablet?
Copixa 5 mg Tablet contains apixaban, a factor Xa inhibitor. This medicine works by blocking a specific clotting factor in the blood, which helps prevent the formation of dangerous clots. It is used to lower the risk of stroke in people with an irregular heartbeat called nonvalvular atrial fibrillation, to prevent clots after hip or knee replacement surgery, and to treat deep vein thrombosis. The tablet is taken by mouth, and the dose is set by your doctor based on your individual needs. Always follow your doctor's instructions and never change the dose on your own.
Uses of Copixa 5 mg Tablet
Copixa 5 mg Tablet is used to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. It is also used to prevent deep vein thrombosis, which can lead to pulmonary embolism, in people who have had hip or knee replacement surgery. Additionally, it is used to treat deep vein thrombosis. Your doctor will determine if this medicine is appropriate for your condition.
How to use Copixa 5 mg Tablet
Take Copixa 5 mg Tablet exactly as your doctor tells you. The dose and how often you take it are decided by your doctor based on your medical condition and other factors. Swallow the tablet whole with water, with or without food. Do not stop taking this medicine without talking to your doctor first, as stopping suddenly can increase the risk of blood clots. If you miss a dose, ask your doctor or pharmacist what to do.
Side effects of Copixa 5 mg Tablet
Copixa 5 mg Tablet can cause side effects. The most important risk is bleeding, as the medicine reduces clotting. Watch for signs such as unusual bruising, nosebleeds, bleeding gums, or blood in urine or stool. A skin rash or severe allergic reaction can also occur. Call your doctor right away if you notice any unusual bleeding or signs of an allergic reaction, such as swelling, difficulty breathing, or severe rash.
Safety and precautions
Before taking Copixa 5 mg Tablet, tell your doctor if you have any bleeding disorders, kidney or liver problems, or if you are pregnant or planning to become pregnant. This medicine may increase the risk of bleeding during pregnancy and delivery. It is not known if apixaban passes into breast milk, so discuss breastfeeding with your doctor. Also inform your doctor about all other medicines you take, especially those that affect blood clotting. Do not stop this medicine without medical advice, as doing so can raise the risk of stroke or other clots.
Frequently asked questions
How should Copixa 5 mg Tablet be taken?
Take Copixa 5 mg Tablet exactly as prescribed by your doctor. The dose and frequency depend on your condition, kidney function, age, and weight. Do not change the dose or stop taking it without consulting your doctor. If you miss a dose, ask your doctor or pharmacist for advice.
What is Copixa 5 mg Tablet used for and what kind of medicine is it?
Copixa 5 mg Tablet is an anticoagulant (blood thinner) that contains apixaban. It is used to reduce the risk of stroke in people with nonvalvular atrial fibrillation, to prevent blood clots after hip or knee replacement surgery, and to treat deep vein thrombosis. It works by inhibiting a clotting factor called factor Xa.
What side effects should I watch for and when should I call my doctor?
Watch for signs of bleeding such as unusual bruising, nosebleeds, bleeding gums, or blood in urine or stool. Also watch for skin rash or signs of a severe allergic reaction like swelling or difficulty breathing. Call your doctor immediately if you notice any of these, especially if bleeding is severe or does not stop.
Can I stop taking Copixa 5 mg Tablet on my own?
No, do not stop taking Copixa 5 mg Tablet without talking to your doctor. Stopping this medicine suddenly can increase the risk of blood clots and stroke. Your doctor will decide if and when it is safe to stop, and may switch you to another anticoagulant if needed.
To reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation
For the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery
... Read more
Apixaban is a factor Xa inhibitor indicated:
To reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation
For the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery
For the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy
Pharmacology
Apixaban acts by inhibiting coagulation, and thus prevents development of blood clots. As a result of FXa inhibition, apixaban prolongs clotting tests such as prothrombin time (PT), INR, and activated partial thromboplastin time (aPTT). Changes observed in these clotting tests at the expected therapeutic dose, however, are small, subject to a high degree of variability, and not useful in monitoring the anticoagulation effect of apixaban.
Dosage & Administration
Recommended Dose: The recommended dose of Apixaban for most patients is 5 mg taken orally twice daily.
Dosage Adjustments: The recommended dose of Apixaban is 2.5 mg twice daily in patients with any 2 of the following characteristics: age ≥80 years, body weight ≤60 kg, serum creatinine ≥1.5mg/dl.
CYP3A4 and P-gp inhibitors: When Apixaban is coadministered with drugs that are strong dual inhibitors of cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) (e.g. ketoconazole, itraconazole, ritonavir, clarithromycin) the recommended dose is 2.5 mg twice daily.
Missed Dose: If a dose of Apixaban is not taken at the scheduled time, the dose should be taken as soon as possible on the same day and twice-daily administration should be resumed. The dose should not be doubled to make up for a missed dose.
Discontinuation for Surgery and Other Interventions: Apixaban should be discontinued at least 48 hours prior to elective surgery or invasive procedures with a moderate or high risk of unacceptable or clinically significant bleeding. Apixaban should be discontinued at least 24 hours prior to elective surgery or invasive procedures with a low risk of bleeding or where the bleeding would be non-critical in location and easily controlled.
Switching from or to Apixaban: Switching from warfarin to Apixaban: Warfarin should be discontinued and Apixaban started when the international normalized ratio (INR) is below 2.0.
Switching from Apixaban to warfarin: Apixaban affects INR, so that INR measurements during co-administration with warfarin may not be useful for determining the appropriate dose of warfarin. If continuous anticoagulation is necessary, discontinue Apixaban and begin both a parenteral anticoagulant and warfarin at the time the next dose of Apixaban would have been taken, discontinuing the parenteral anticoagulant when INR reaches an acceptable range.
Switching between Apixaban and anticoagulants other than warfarin: Discontinue one being taken and begin the other at the next scheduled dose.
Interaction
Apixaban is a substrate of both CYP3A4 and P-gp. Inhibitors of CYP3A4 and P-gp increase exposure to Apixaban and increase the risk of bleeding. Inducers of CYP3A4 and P-gp decrease exposure to Apixaban and increase the risk of stroke.
Contraindications
Apixaban is contraindicated in patients with the following conditions: Active pathological bleeding. Severe hypersensitivity reaction to Apixaban (i.e. anaphylactic reactions).
Side Effects
Apixaban can cause a skin rash or severe allergic reaction.
Pregnancy & Lactation
Pregnancy: There are no adequate and well-controlled studies of Apixaban in pregnant women. Treatment is likely to increase the risk of hemorrhage during pregnancy and delivery. Apixaban should be used during pregnancy only if the potential benefit outweighs the potential risk to the mother and fetus.
Labor and Delivery: Safety and effectiveness of Apixaban during labor and delivery have not been studied in clinical trials. Consider the risks of bleeding and of stroke in using Apixaban in this condition.
Nursing Mothers: It is unknown whether Apixaban or its metabolites are excreted in human milk. Women should be instructed either to discontinue breastfeeding or to discontinue Apixaban therapy, taking into account the importance of the drug to the mother.
Precautions & Warnings
Increased Risk of Stroke with Discontinuation of Apixaban Discontinuing Apixaban in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. An increased rate of stroke was observed during the transition from Apixaban to warfarin in clinical trials in patients with nonvalvular atrial fibrillation. If Apixaban must be discontinued for a reason other than pathological bleeding, consider coverage with another anticoagulant.
Overdose Effects
There is no antidote to Apixaban. Overdose of Apixaban increases the risk of bleeding. Activated charcoal may be useful in the management of Apixaban overdose.
Storage Conditions
Keep in a dry place and store below 30°C. Protect from light and keep out of the reach of children.
Alternative brands of Apixaban
Other brands with the same generic name, cheapest first.